View ValuationM3 향후 성장Future 기준 점검 2/6M3 (는) 각각 연간 12.1% 및 9.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 12.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.2% 로 예상됩니다.핵심 정보12.1%이익 성장률12.59%EPS 성장률Healthcare Services 이익 성장19.8%매출 성장률9.3%향후 자기자본이익률14.18%애널리스트 커버리지Good마지막 업데이트07 Aug 2026최근 향후 성장 업데이트공고 • Aug 07M3, Inc. Provides Consolidated Earnings Guidance for the six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027M3, Inc. provided consolidated earnings guidance for the six months ending September 30, 2026 and fiscal year ending March 31, 2027. For the six months, the company expects revenue of JPY 192,000 million, operating profit of JPY 37,000 million, profit of JPY 26,000 million, profit attributable to owners of the parent of JPY 24,000 million, and basic earnings per share of JPY 35.45. For the fiscal year, the company expects revenue of JPY 400,000 million, operating profit of JPY 80,000 million, profit of JPY 56,000 million, profit attributable to owners of the parent of JPY 53,000 million, and basic earnings per share of JPY 78.29.공고 • Feb 10M3, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025M3, Inc. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the period, the company expected revenue to be in the range of JPY 268,000 million to JPY 273,000 million, operating profit to be in the range of JPY 67,000 million to JPY 70,000 million, profit attributable to owners of the parent to be in the range of JPY 44,000 million to JPY 46,000 million and basic earnings per share to be in the range of JPY 64.80 to JPY 67.75.공고 • Oct 29M3, Inc. Provides Consolidated Earnings Guidance for the Full Fiscal Year Ending March 31, 2024M3, Inc. provided Consolidated earnings guidance for the full Fiscal Year Ending March 31, 2024. For the year, company expects Net sales of JPY 250,000 million, Operating profit of JPY 75,000 million, Net profit of JPY 52,000 million, Net profit attributable to owners of the parent of JPY 50,000 million and Basic earnings per share of JPY 73.65.공고 • Jul 30M3, Inc. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and the Full Year Ending March 31, 2024M3, Inc. provided consolidated earnings guidance for the six months ending September 30, 2023 and the full year ending March 31, 2024. For the six months ending September 30, 2023, the company expects net sales of ¥120,000 million, Operating profit of ¥32,000 million and Net profit of ¥22,200 million or ¥31.37 basic per share. The company expects profit attributable to owners of the parent company of ¥21,300 million.For the year ending March 31, 2024, the company expects net sales of ¥250,000 million, Operating profit of ¥75,000 million and Net profit of ¥52,000 million or ¥73.65 basic per share. The company expects profit attributable to owners of the parent company of ¥50,000 million.모든 업데이트 보기Recent updatesBoard Change • Aug 10Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Outside Director Makiko Shinoda was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공고 • Aug 07M3, Inc. Provides Consolidated Earnings Guidance for the six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027M3, Inc. provided consolidated earnings guidance for the six months ending September 30, 2026 and fiscal year ending March 31, 2027. For the six months, the company expects revenue of JPY 192,000 million, operating profit of JPY 37,000 million, profit of JPY 26,000 million, profit attributable to owners of the parent of JPY 24,000 million, and basic earnings per share of JPY 35.45. For the fiscal year, the company expects revenue of JPY 400,000 million, operating profit of JPY 80,000 million, profit of JPY 56,000 million, profit attributable to owners of the parent of JPY 53,000 million, and basic earnings per share of JPY 78.29.공고 • Jun 09M3, Inc. to Report Q1, 2027 Results on Aug 06, 2026M3, Inc. announced that they will report Q1, 2027 results on Aug 06, 2026공고 • Jun 05M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK.M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK on June 5, 2026. For the period ending June 30, 2025, Wiseman Co. Ltd reported total revenue of ¥12.38 billion, operating loss of ¥222 million and net loss of ¥170 million. As of June 30, 2025, Wiseman Co. Ltd reported total assets of ¥20.03 billion and total common equity of ¥2.74 billion. The expected completion of the transaction is July 1, 2026.공고 • May 02M3, Inc., Annual General Meeting, Jun 26, 2026M3, Inc., Annual General Meeting, Jun 26, 2026.공고 • Apr 22M3, Inc. to Report Fiscal Year 2026 Results on May 01, 2026M3, Inc. announced that they will report fiscal year 2026 results on May 01, 2026공고 • Nov 29M3, Inc. to Report Q3, 2026 Results on Feb 04, 2026M3, Inc. announced that they will report Q3, 2026 results on Feb 04, 2026Board Change • Nov 24Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Sep 04Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion.Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion on September 2, 2025. A cash consideration of ¥19.08 billion will be paid by Intermestic Inc. As part of consideration, ¥19.08 billion is paid towards common equity of Horus Co., Ltd. The transaction will be financed through senior debt of ¥18 billion. For the period ending April 30, 2025, Horus Co., Ltd. reported total revenue of ¥28.19 billion and EBIT of ¥1.84 billion. As of April 30, 2025, Horus Co., Ltd. reported total assets of ¥19.95 billion and total common equity of ¥4.42 billion. The expected completion of the transaction is October 1, 2025.공고 • Sep 01M3, Inc. to Report Q2, 2026 Results on Nov 12, 2025M3, Inc. announced that they will report Q2, 2026 results on Nov 12, 2025공고 • Jun 05EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders.EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders on June 5, 2025. EUCALIA Inc acquired 0.053 shares in Epigno Inc. The sellers were 19.9% stake from M3, Inc., 9.4% stake from M3 Career, Inc., 11.7% stake from THVP-No. 1 Limited Partnership, a fund managed by Tohoku University Venture Partners Co.,Ltd., 22.5% stake from Fumiyoshi Inui,12.1% stake from Takuya Shiga. The other sellers were Lifetime Ventures Investment LP, Kanshin Mirai No.2 Investment LP, Healthcare New Frontier Investment LP, and Colopl Next No.7 Fund Investment LP. For the period ending August 31, 2024, Epigno Inc. reported total revenue of approximately ¥110 million, operating loss of ¥83.7 million, net loss of ¥81.19 million, total assets of approximately ¥190 million and net assets of ¥23.3 million. The transaction is expected to close on July 1, 2025.공고 • May 31M3, Inc. to Report Q1, 2026 Results on Aug 06, 2025M3, Inc. announced that they will report Q1, 2026 results on Aug 06, 2025공고 • May 03M3, Inc. (TSE:2413) announces an Equity Buyback for 20,000,000 shares, representing 2.95% for ¥20,000 million.M3, Inc. (TSE:2413) announces a share repurchase program. Under the program, the company will repurchase up to 20,000,000 shares, representing 2.95% of its total shares outstanding (excluding treasury shares), for a total of ¥20,000 million. The purpose of repurchase program is to provide returns to shareholders. The repurchase program is valid till April 30, 2026. As of March 31, 2025, the company had 679,032,629 shares issued (excluding treasury shares) and 45,271 treasury shares공고 • May 02+ 2 more updatesM3, Inc., Annual General Meeting, Jun 26, 2025M3, Inc., Annual General Meeting, Jun 26, 2025.Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €9.30, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 18x in the Healthcare Services industry in Europe. Total loss to shareholders of 70% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €10.96 per share.Board Change • Apr 07Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 2 independent directors. 9 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improves as stock rises 25%After last week's 25% share price gain to €11.40, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 20x in the Healthcare Services industry in Europe. Total loss to shareholders of 8.6% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €13.87 per share.Board Change • Mar 18Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 2 independent directors. 9 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공고 • Mar 07M3, Inc. (TSE:2413) entered into Share transfer agreement to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion.M3, Inc. (TSE:2413) agreed to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion on March 5, 2025. A cash consideration of ¥10.2 billion will be paid by M3, Inc. As part of consideration, ¥10.2 billion is paid towards common equity of Ewel Inc. The transaction will be financed through Cash on Hand of ¥10.2 billion. For the period ending March 31, 2024, Ewel Inc. reported total revenue of ¥11.67 billion, EBIT of ¥887 million and net income of ¥566 million. As of March 31, 2024, Ewel Inc. reported total assets of ¥13.65 billion and total common equity of ¥5.88 billion. The expected completion of the transaction is April 1, 2025.공고 • Mar 01M3, Inc. to Report Fiscal Year 2025 Results on May 02, 2025M3, Inc. announced that they will report fiscal year 2025 results on May 02, 2025공고 • Feb 10M3, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025M3, Inc. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the period, the company expected revenue to be in the range of JPY 268,000 million to JPY 273,000 million, operating profit to be in the range of JPY 67,000 million to JPY 70,000 million, profit attributable to owners of the parent to be in the range of JPY 44,000 million to JPY 46,000 million and basic earnings per share to be in the range of JPY 64.80 to JPY 67.75.공고 • Nov 30M3, Inc. to Report Q3, 2025 Results on Feb 10, 2025M3, Inc. announced that they will report Q3, 2025 results on Feb 10, 2025Reported Earnings • Nov 01Second quarter 2025 earnings released: EPS: JP¥8.90 (vs JP¥16.19 in 2Q 2024)Second quarter 2025 results: EPS: JP¥8.90 (down from JP¥16.19 in 2Q 2024). Revenue: JP¥60.6b (up 3.8% from 2Q 2024). Net income: JP¥6.05b (down 45% from 2Q 2024). Profit margin: 10.0% (down from 19% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Healthcare Services industry in Europe.Board Change • Sep 24Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 2 independent directors. 10 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공고 • Aug 27M3, Inc. to Report Q2, 2025 Results on Oct 30, 2024M3, Inc. announced that they will report Q2, 2025 results on Oct 30, 2024Board Change • Jun 10Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공고 • Jun 03M3, Inc. to Report Q1, 2025 Results on Jul 26, 2024M3, Inc. announced that they will report Q1, 2025 results on Jul 26, 2024Valuation Update With 7 Day Price Move • May 03Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to €10.00, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Healthcare Services industry in Europe.Reported Earnings • May 02Full year 2024 earnings released: EPS: JP¥66.68 (vs JP¥72.22 in FY 2023)Full year 2024 results: EPS: JP¥66.68 (down from JP¥72.22 in FY 2023). Revenue: JP¥238.9b (up 3.5% from FY 2023). Net income: JP¥45.3b (down 7.7% from FY 2023). Profit margin: 19% (down from 21% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in Europe.Board Change • May 02Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공고 • Apr 28+ 1 more updateM3, Inc., Annual General Meeting, Jun 26, 2024M3, Inc., Annual General Meeting, Jun 26, 2024.Upcoming Dividend • Mar 21Upcoming dividend of JP¥21.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 12 June 2024. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (1.5%).Board Change • Mar 11Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공고 • Mar 02M3, Inc. to Report Fiscal Year 2024 Results on Apr 26, 2024M3, Inc. announced that they will report fiscal year 2024 results on Apr 26, 2024Reported Earnings • Feb 02Third quarter 2024 earnings released: EPS: JP¥19.45 (vs JP¥22.42 in 3Q 2023)Third quarter 2024 results: EPS: JP¥19.45 (down from JP¥22.42 in 3Q 2023). Revenue: JP¥63.4b (up 1.4% from 3Q 2023). Net income: JP¥13.2b (down 13% from 3Q 2023). Profit margin: 21% (down from 24% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Healthcare Services industry in Europe.Board Change • Dec 11Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공고 • Nov 29M3, Inc. to Report Q3, 2024 Results on Jan 31, 2024M3, Inc. announced that they will report Q3, 2024 results on Jan 31, 2024공고 • Nov 16M3, Inc. (TSE:2413) entered into a share tender agreement to acquire a 55% stake in Benefit One Inc. (TSE:2412) from Pasona Group Inc. (TSE:2168) and others for approximately ¥140 billion.M3, Inc. (TSE:2413) entered into a share tender agreement to acquire a 55% stake in Benefit One Inc. (TSE:2412) from Pasona Group Inc. (TSE:2168) and others for approximately ¥140 billion on November 14, 2023. The offer price is ¥1600 cash per share. The transaction is subject to minimum tender of 81,210,400 shares and maximum of 87,307,300 shares. The offer period will commence on November 15, 2023 and end on December 13, 2023.Reported Earnings • Oct 30Second quarter 2024 earnings released: EPS: JP¥18.51 (vs JP¥17.58 in 2Q 2023)Second quarter 2024 results: EPS: JP¥18.51 (up from JP¥17.58 in 2Q 2023). Revenue: JP¥57.9b (up 4.1% from 2Q 2023). Net income: JP¥12.6b (up 5.3% from 2Q 2023). Profit margin: 22% (in line with 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Healthcare Services industry in Europe.공고 • Oct 29M3, Inc. Provides Consolidated Earnings Guidance for the Full Fiscal Year Ending March 31, 2024M3, Inc. provided Consolidated earnings guidance for the full Fiscal Year Ending March 31, 2024. For the year, company expects Net sales of JPY 250,000 million, Operating profit of JPY 75,000 million, Net profit of JPY 52,000 million, Net profit attributable to owners of the parent of JPY 50,000 million and Basic earnings per share of JPY 73.65.Board Change • Oct 18Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공고 • Aug 30M3, Inc. to Report Q2, 2024 Results on Oct 27, 2023M3, Inc. announced that they will report Q2, 2024 results on Oct 27, 2023공고 • Aug 22M3, Inc. (TSE:2413) acquired Messly Limited.M3, Inc. (TSE:2413) acquired Messly Limited on August 21, 2023.M3, Inc. (TSE:2413) completed the acquisition of Messly Limited on August 21, 2023.공고 • Aug 08M3, Inc. (TSE:2413) acquired frogwell corporation.M3, Inc. (TSE:2413) acquired frogwell corporation on August 7, 2023.M3, Inc. (TSE:2413) completed the acquisition of frogwell corporation on August 7, 2023.공고 • Jul 30M3, Inc. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and the Full Year Ending March 31, 2024M3, Inc. provided consolidated earnings guidance for the six months ending September 30, 2023 and the full year ending March 31, 2024. For the six months ending September 30, 2023, the company expects net sales of ¥120,000 million, Operating profit of ¥32,000 million and Net profit of ¥22,200 million or ¥31.37 basic per share. The company expects profit attributable to owners of the parent company of ¥21,300 million.For the year ending March 31, 2024, the company expects net sales of ¥250,000 million, Operating profit of ¥75,000 million and Net profit of ¥52,000 million or ¥73.65 basic per share. The company expects profit attributable to owners of the parent company of ¥50,000 million.New Risk • Jun 23New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 21% Last year net profit margin: 31% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Profit margins are more than 30% lower than last year (21% net profit margin).Board Change • Jun 23No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Rie Nakamura was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공고 • May 28M3, Inc. to Report Q1, 2024 Results on Jul 28, 2023M3, Inc. announced that they will report Q1, 2024 results on Jul 28, 2023공고 • Feb 04M3, Inc. (TSE:2413) acquired Michael Allen Company.M3, Inc. (TSE:2413) acquired Michael Allen Company on February 3, 2023.M3, Inc. (TSE:2413) completed the acquisition of Michael Allen Company on February 3, 2023.공고 • Nov 24M3, Inc. to Report Q3, 2023 Results on Feb 03, 2023M3, Inc. announced that they will report Q3, 2023 results on Feb 03, 2023공고 • Sep 30M3, Inc. (TSE:2413) acquired Rinkai Medical Service.M3, Inc. (TSE:2413) acquired Rinkai Medical Service on September 28, 2022. M3, Inc. (TSE:2413) completed the acquisition of Rinkai Medical Service on September 28, 2022.공고 • Aug 25M3, Inc. to Report Q2, 2023 Results on Nov 02, 2022M3, Inc. announced that they will report Q2, 2023 results on Nov 02, 2022Reported Earnings • Jul 28First quarter 2023 earnings released: EPS: JP¥19.87 (vs JP¥23.23 in 1Q 2022)First quarter 2023 results: EPS: JP¥19.87 (down from JP¥23.23 in 1Q 2022). Revenue: JP¥57.0b (up 23% from 1Q 2022). Net income: JP¥13.5b (down 14% from 1Q 2022). Profit margin: 24% (down from 34% in 1Q 2022). Over the next year, revenue is forecast to grow 10%, compared to a 16% growth forecast for the industry in Germany.Board Change • Jul 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Rie Nakamura was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Jun 09M3, Inc. (TSE:2413) acquired Edoctores Soluciones.M3, Inc. (TSE:2413) acquired Edoctores Soluciones on June 8, 2022. M3, Inc. (TSE:2413) completed the acquisition of Edoctores Soluciones on June 8, 2022.공고 • May 25M3, Inc. to Report Q1, 2023 Results on Jul 27, 2022M3, Inc. announced that they will report Q1, 2023 results on Jul 27, 2022Board Change • May 12No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. No independent directors (6 non-independent directors). Director Kazuyuki Izumiya was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공고 • Apr 28M3, Inc. Announces Dividend for the Year Ended March 31, 2022, Payable on June 13, 2022M3, Inc. announced a dividend of ¥16.00 per share for the year ended March 31, 2022 against ¥12.00 per share paid a year ago. Dividend payment commencement date is on June 13, 2022.공고 • Apr 07M3, Inc. to Report Q4, 2022 Results on Apr 27, 2022M3, Inc. announced that they will report Q4, 2022 results on Apr 27, 2022Board Change • Mar 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. Director Kazuyuki Izumiya was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.이익 및 매출 성장 예측MUN:4YC - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/2029471,01966,91964,980N/A103/31/2028428,05959,81259,497N/A133/31/2027391,59953,62553,092N/A136/30/2026355,26846,143N/AN/AN/A3/31/2026351,36349,10058,33270,262N/A12/31/2025343,77449,590N/AN/AN/A9/30/2025330,96645,90153,10464,411N/A6/30/2025306,89141,076N/AN/AN/A3/31/2025284,90040,48442,75251,743N/A12/31/2024265,21541,201N/AN/AN/A9/30/2024247,90739,15949,25555,084N/A6/30/2024245,69644,105N/AN/AN/A3/31/2024238,88345,27150,72958,310N/A12/31/2023234,85246,36348,07459,340N/A9/30/2023233,99748,37448,07458,719N/A6/30/2023231,21849,31549,92459,680N/A3/31/2023230,81849,02849,53657,113N/A12/31/2022229,14546,95549,78754,523N/A9/30/2022223,12847,11754,60958,728N/A6/30/2022218,75260,20349,56553,415N/A3/31/2022208,15963,84548,89152,108N/A12/31/2021199,61767,28046,17848,867N/A9/30/2021191,82363,90044,51746,894N/A6/30/2021180,12347,12445,53147,375N/A3/31/2021169,19837,82244,63846,627N/A12/31/2020158,40431,76038,20540,464N/A9/30/2020144,45026,52031,61734,196N/A6/30/2020135,68523,19026,40529,364N/A3/31/2020130,97321,635N/A26,789N/A12/31/2019125,70421,589N/A26,246N/A9/30/2019121,32920,887N/A19,995N/A6/30/2019116,92719,865N/A19,463N/A3/31/2019113,05919,577N/A17,749N/A12/31/2018109,58519,532N/A13,931N/A9/30/2018104,89719,796N/A16,717N/A6/30/201899,49519,580N/A15,908N/A3/31/201894,47119,684N/A15,913N/A12/31/201790,40218,934N/A16,314N/A9/30/201786,11817,830N/A17,543N/A6/30/201781,96017,303N/A17,382N/A3/31/201778,14316,004N/A16,555N/A12/31/201673,57014,871N/A14,848N/A9/30/201669,00913,526N/A14,631N/A6/30/201667,18912,953N/A13,813N/A3/31/201664,66012,508N/A12,136N/A12/31/201560,28811,664N/A10,106N/A9/30/201557,24110,874N/A9,879N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 4YC 의 연간 예상 수익 증가율(12.1%)이 saving rate(2.1%)보다 높습니다.수익 vs 시장: 4YC 의 연간 수익(12.1%)이 German 시장(15.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 4YC 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 4YC 의 수익(연간 9.3%)이 German 시장(연간 6.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 4YC 의 수익(연간 9.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 4YC의 자본 수익률은 3년 후 14.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/12 03:57종가2026/08/10 00:00수익2026/06/30연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스M3, Inc.는 21명의 분석가가 다루고 있습니다. 이 중 13명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ritsuo WatanabeBofA Global ResearchLuoxin JiangCitic Securities Co., Ltd.Shuo SongCitic Securities Co., Ltd.18명의 분석가 더 보기
공고 • Aug 07M3, Inc. Provides Consolidated Earnings Guidance for the six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027M3, Inc. provided consolidated earnings guidance for the six months ending September 30, 2026 and fiscal year ending March 31, 2027. For the six months, the company expects revenue of JPY 192,000 million, operating profit of JPY 37,000 million, profit of JPY 26,000 million, profit attributable to owners of the parent of JPY 24,000 million, and basic earnings per share of JPY 35.45. For the fiscal year, the company expects revenue of JPY 400,000 million, operating profit of JPY 80,000 million, profit of JPY 56,000 million, profit attributable to owners of the parent of JPY 53,000 million, and basic earnings per share of JPY 78.29.
공고 • Feb 10M3, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025M3, Inc. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the period, the company expected revenue to be in the range of JPY 268,000 million to JPY 273,000 million, operating profit to be in the range of JPY 67,000 million to JPY 70,000 million, profit attributable to owners of the parent to be in the range of JPY 44,000 million to JPY 46,000 million and basic earnings per share to be in the range of JPY 64.80 to JPY 67.75.
공고 • Oct 29M3, Inc. Provides Consolidated Earnings Guidance for the Full Fiscal Year Ending March 31, 2024M3, Inc. provided Consolidated earnings guidance for the full Fiscal Year Ending March 31, 2024. For the year, company expects Net sales of JPY 250,000 million, Operating profit of JPY 75,000 million, Net profit of JPY 52,000 million, Net profit attributable to owners of the parent of JPY 50,000 million and Basic earnings per share of JPY 73.65.
공고 • Jul 30M3, Inc. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and the Full Year Ending March 31, 2024M3, Inc. provided consolidated earnings guidance for the six months ending September 30, 2023 and the full year ending March 31, 2024. For the six months ending September 30, 2023, the company expects net sales of ¥120,000 million, Operating profit of ¥32,000 million and Net profit of ¥22,200 million or ¥31.37 basic per share. The company expects profit attributable to owners of the parent company of ¥21,300 million.For the year ending March 31, 2024, the company expects net sales of ¥250,000 million, Operating profit of ¥75,000 million and Net profit of ¥52,000 million or ¥73.65 basic per share. The company expects profit attributable to owners of the parent company of ¥50,000 million.
Board Change • Aug 10Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Outside Director Makiko Shinoda was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공고 • Aug 07M3, Inc. Provides Consolidated Earnings Guidance for the six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027M3, Inc. provided consolidated earnings guidance for the six months ending September 30, 2026 and fiscal year ending March 31, 2027. For the six months, the company expects revenue of JPY 192,000 million, operating profit of JPY 37,000 million, profit of JPY 26,000 million, profit attributable to owners of the parent of JPY 24,000 million, and basic earnings per share of JPY 35.45. For the fiscal year, the company expects revenue of JPY 400,000 million, operating profit of JPY 80,000 million, profit of JPY 56,000 million, profit attributable to owners of the parent of JPY 53,000 million, and basic earnings per share of JPY 78.29.
공고 • Jun 09M3, Inc. to Report Q1, 2027 Results on Aug 06, 2026M3, Inc. announced that they will report Q1, 2027 results on Aug 06, 2026
공고 • Jun 05M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK.M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK on June 5, 2026. For the period ending June 30, 2025, Wiseman Co. Ltd reported total revenue of ¥12.38 billion, operating loss of ¥222 million and net loss of ¥170 million. As of June 30, 2025, Wiseman Co. Ltd reported total assets of ¥20.03 billion and total common equity of ¥2.74 billion. The expected completion of the transaction is July 1, 2026.
공고 • May 02M3, Inc., Annual General Meeting, Jun 26, 2026M3, Inc., Annual General Meeting, Jun 26, 2026.
공고 • Apr 22M3, Inc. to Report Fiscal Year 2026 Results on May 01, 2026M3, Inc. announced that they will report fiscal year 2026 results on May 01, 2026
공고 • Nov 29M3, Inc. to Report Q3, 2026 Results on Feb 04, 2026M3, Inc. announced that they will report Q3, 2026 results on Feb 04, 2026
Board Change • Nov 24Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Sep 04Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion.Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion on September 2, 2025. A cash consideration of ¥19.08 billion will be paid by Intermestic Inc. As part of consideration, ¥19.08 billion is paid towards common equity of Horus Co., Ltd. The transaction will be financed through senior debt of ¥18 billion. For the period ending April 30, 2025, Horus Co., Ltd. reported total revenue of ¥28.19 billion and EBIT of ¥1.84 billion. As of April 30, 2025, Horus Co., Ltd. reported total assets of ¥19.95 billion and total common equity of ¥4.42 billion. The expected completion of the transaction is October 1, 2025.
공고 • Sep 01M3, Inc. to Report Q2, 2026 Results on Nov 12, 2025M3, Inc. announced that they will report Q2, 2026 results on Nov 12, 2025
공고 • Jun 05EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders.EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders on June 5, 2025. EUCALIA Inc acquired 0.053 shares in Epigno Inc. The sellers were 19.9% stake from M3, Inc., 9.4% stake from M3 Career, Inc., 11.7% stake from THVP-No. 1 Limited Partnership, a fund managed by Tohoku University Venture Partners Co.,Ltd., 22.5% stake from Fumiyoshi Inui,12.1% stake from Takuya Shiga. The other sellers were Lifetime Ventures Investment LP, Kanshin Mirai No.2 Investment LP, Healthcare New Frontier Investment LP, and Colopl Next No.7 Fund Investment LP. For the period ending August 31, 2024, Epigno Inc. reported total revenue of approximately ¥110 million, operating loss of ¥83.7 million, net loss of ¥81.19 million, total assets of approximately ¥190 million and net assets of ¥23.3 million. The transaction is expected to close on July 1, 2025.
공고 • May 31M3, Inc. to Report Q1, 2026 Results on Aug 06, 2025M3, Inc. announced that they will report Q1, 2026 results on Aug 06, 2025
공고 • May 03M3, Inc. (TSE:2413) announces an Equity Buyback for 20,000,000 shares, representing 2.95% for ¥20,000 million.M3, Inc. (TSE:2413) announces a share repurchase program. Under the program, the company will repurchase up to 20,000,000 shares, representing 2.95% of its total shares outstanding (excluding treasury shares), for a total of ¥20,000 million. The purpose of repurchase program is to provide returns to shareholders. The repurchase program is valid till April 30, 2026. As of March 31, 2025, the company had 679,032,629 shares issued (excluding treasury shares) and 45,271 treasury shares
공고 • May 02+ 2 more updatesM3, Inc., Annual General Meeting, Jun 26, 2025M3, Inc., Annual General Meeting, Jun 26, 2025.
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €9.30, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 18x in the Healthcare Services industry in Europe. Total loss to shareholders of 70% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €10.96 per share.
Board Change • Apr 07Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 2 independent directors. 9 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improves as stock rises 25%After last week's 25% share price gain to €11.40, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 20x in the Healthcare Services industry in Europe. Total loss to shareholders of 8.6% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €13.87 per share.
Board Change • Mar 18Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 2 independent directors. 9 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공고 • Mar 07M3, Inc. (TSE:2413) entered into Share transfer agreement to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion.M3, Inc. (TSE:2413) agreed to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion on March 5, 2025. A cash consideration of ¥10.2 billion will be paid by M3, Inc. As part of consideration, ¥10.2 billion is paid towards common equity of Ewel Inc. The transaction will be financed through Cash on Hand of ¥10.2 billion. For the period ending March 31, 2024, Ewel Inc. reported total revenue of ¥11.67 billion, EBIT of ¥887 million and net income of ¥566 million. As of March 31, 2024, Ewel Inc. reported total assets of ¥13.65 billion and total common equity of ¥5.88 billion. The expected completion of the transaction is April 1, 2025.
공고 • Mar 01M3, Inc. to Report Fiscal Year 2025 Results on May 02, 2025M3, Inc. announced that they will report fiscal year 2025 results on May 02, 2025
공고 • Feb 10M3, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025M3, Inc. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the period, the company expected revenue to be in the range of JPY 268,000 million to JPY 273,000 million, operating profit to be in the range of JPY 67,000 million to JPY 70,000 million, profit attributable to owners of the parent to be in the range of JPY 44,000 million to JPY 46,000 million and basic earnings per share to be in the range of JPY 64.80 to JPY 67.75.
공고 • Nov 30M3, Inc. to Report Q3, 2025 Results on Feb 10, 2025M3, Inc. announced that they will report Q3, 2025 results on Feb 10, 2025
Reported Earnings • Nov 01Second quarter 2025 earnings released: EPS: JP¥8.90 (vs JP¥16.19 in 2Q 2024)Second quarter 2025 results: EPS: JP¥8.90 (down from JP¥16.19 in 2Q 2024). Revenue: JP¥60.6b (up 3.8% from 2Q 2024). Net income: JP¥6.05b (down 45% from 2Q 2024). Profit margin: 10.0% (down from 19% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Healthcare Services industry in Europe.
Board Change • Sep 24Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 2 independent directors. 10 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공고 • Aug 27M3, Inc. to Report Q2, 2025 Results on Oct 30, 2024M3, Inc. announced that they will report Q2, 2025 results on Oct 30, 2024
Board Change • Jun 10Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공고 • Jun 03M3, Inc. to Report Q1, 2025 Results on Jul 26, 2024M3, Inc. announced that they will report Q1, 2025 results on Jul 26, 2024
Valuation Update With 7 Day Price Move • May 03Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to €10.00, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Healthcare Services industry in Europe.
Reported Earnings • May 02Full year 2024 earnings released: EPS: JP¥66.68 (vs JP¥72.22 in FY 2023)Full year 2024 results: EPS: JP¥66.68 (down from JP¥72.22 in FY 2023). Revenue: JP¥238.9b (up 3.5% from FY 2023). Net income: JP¥45.3b (down 7.7% from FY 2023). Profit margin: 19% (down from 21% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in Europe.
Board Change • May 02Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공고 • Apr 28+ 1 more updateM3, Inc., Annual General Meeting, Jun 26, 2024M3, Inc., Annual General Meeting, Jun 26, 2024.
Upcoming Dividend • Mar 21Upcoming dividend of JP¥21.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 12 June 2024. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (1.5%).
Board Change • Mar 11Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공고 • Mar 02M3, Inc. to Report Fiscal Year 2024 Results on Apr 26, 2024M3, Inc. announced that they will report fiscal year 2024 results on Apr 26, 2024
Reported Earnings • Feb 02Third quarter 2024 earnings released: EPS: JP¥19.45 (vs JP¥22.42 in 3Q 2023)Third quarter 2024 results: EPS: JP¥19.45 (down from JP¥22.42 in 3Q 2023). Revenue: JP¥63.4b (up 1.4% from 3Q 2023). Net income: JP¥13.2b (down 13% from 3Q 2023). Profit margin: 21% (down from 24% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Healthcare Services industry in Europe.
Board Change • Dec 11Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공고 • Nov 29M3, Inc. to Report Q3, 2024 Results on Jan 31, 2024M3, Inc. announced that they will report Q3, 2024 results on Jan 31, 2024
공고 • Nov 16M3, Inc. (TSE:2413) entered into a share tender agreement to acquire a 55% stake in Benefit One Inc. (TSE:2412) from Pasona Group Inc. (TSE:2168) and others for approximately ¥140 billion.M3, Inc. (TSE:2413) entered into a share tender agreement to acquire a 55% stake in Benefit One Inc. (TSE:2412) from Pasona Group Inc. (TSE:2168) and others for approximately ¥140 billion on November 14, 2023. The offer price is ¥1600 cash per share. The transaction is subject to minimum tender of 81,210,400 shares and maximum of 87,307,300 shares. The offer period will commence on November 15, 2023 and end on December 13, 2023.
Reported Earnings • Oct 30Second quarter 2024 earnings released: EPS: JP¥18.51 (vs JP¥17.58 in 2Q 2023)Second quarter 2024 results: EPS: JP¥18.51 (up from JP¥17.58 in 2Q 2023). Revenue: JP¥57.9b (up 4.1% from 2Q 2023). Net income: JP¥12.6b (up 5.3% from 2Q 2023). Profit margin: 22% (in line with 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Healthcare Services industry in Europe.
공고 • Oct 29M3, Inc. Provides Consolidated Earnings Guidance for the Full Fiscal Year Ending March 31, 2024M3, Inc. provided Consolidated earnings guidance for the full Fiscal Year Ending March 31, 2024. For the year, company expects Net sales of JPY 250,000 million, Operating profit of JPY 75,000 million, Net profit of JPY 52,000 million, Net profit attributable to owners of the parent of JPY 50,000 million and Basic earnings per share of JPY 73.65.
Board Change • Oct 18Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공고 • Aug 30M3, Inc. to Report Q2, 2024 Results on Oct 27, 2023M3, Inc. announced that they will report Q2, 2024 results on Oct 27, 2023
공고 • Aug 22M3, Inc. (TSE:2413) acquired Messly Limited.M3, Inc. (TSE:2413) acquired Messly Limited on August 21, 2023.M3, Inc. (TSE:2413) completed the acquisition of Messly Limited on August 21, 2023.
공고 • Aug 08M3, Inc. (TSE:2413) acquired frogwell corporation.M3, Inc. (TSE:2413) acquired frogwell corporation on August 7, 2023.M3, Inc. (TSE:2413) completed the acquisition of frogwell corporation on August 7, 2023.
공고 • Jul 30M3, Inc. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and the Full Year Ending March 31, 2024M3, Inc. provided consolidated earnings guidance for the six months ending September 30, 2023 and the full year ending March 31, 2024. For the six months ending September 30, 2023, the company expects net sales of ¥120,000 million, Operating profit of ¥32,000 million and Net profit of ¥22,200 million or ¥31.37 basic per share. The company expects profit attributable to owners of the parent company of ¥21,300 million.For the year ending March 31, 2024, the company expects net sales of ¥250,000 million, Operating profit of ¥75,000 million and Net profit of ¥52,000 million or ¥73.65 basic per share. The company expects profit attributable to owners of the parent company of ¥50,000 million.
New Risk • Jun 23New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 21% Last year net profit margin: 31% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Profit margins are more than 30% lower than last year (21% net profit margin).
Board Change • Jun 23No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Rie Nakamura was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • May 28M3, Inc. to Report Q1, 2024 Results on Jul 28, 2023M3, Inc. announced that they will report Q1, 2024 results on Jul 28, 2023
공고 • Feb 04M3, Inc. (TSE:2413) acquired Michael Allen Company.M3, Inc. (TSE:2413) acquired Michael Allen Company on February 3, 2023.M3, Inc. (TSE:2413) completed the acquisition of Michael Allen Company on February 3, 2023.
공고 • Nov 24M3, Inc. to Report Q3, 2023 Results on Feb 03, 2023M3, Inc. announced that they will report Q3, 2023 results on Feb 03, 2023
공고 • Sep 30M3, Inc. (TSE:2413) acquired Rinkai Medical Service.M3, Inc. (TSE:2413) acquired Rinkai Medical Service on September 28, 2022. M3, Inc. (TSE:2413) completed the acquisition of Rinkai Medical Service on September 28, 2022.
공고 • Aug 25M3, Inc. to Report Q2, 2023 Results on Nov 02, 2022M3, Inc. announced that they will report Q2, 2023 results on Nov 02, 2022
Reported Earnings • Jul 28First quarter 2023 earnings released: EPS: JP¥19.87 (vs JP¥23.23 in 1Q 2022)First quarter 2023 results: EPS: JP¥19.87 (down from JP¥23.23 in 1Q 2022). Revenue: JP¥57.0b (up 23% from 1Q 2022). Net income: JP¥13.5b (down 14% from 1Q 2022). Profit margin: 24% (down from 34% in 1Q 2022). Over the next year, revenue is forecast to grow 10%, compared to a 16% growth forecast for the industry in Germany.
Board Change • Jul 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Rie Nakamura was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Jun 09M3, Inc. (TSE:2413) acquired Edoctores Soluciones.M3, Inc. (TSE:2413) acquired Edoctores Soluciones on June 8, 2022. M3, Inc. (TSE:2413) completed the acquisition of Edoctores Soluciones on June 8, 2022.
공고 • May 25M3, Inc. to Report Q1, 2023 Results on Jul 27, 2022M3, Inc. announced that they will report Q1, 2023 results on Jul 27, 2022
Board Change • May 12No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. No independent directors (6 non-independent directors). Director Kazuyuki Izumiya was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공고 • Apr 28M3, Inc. Announces Dividend for the Year Ended March 31, 2022, Payable on June 13, 2022M3, Inc. announced a dividend of ¥16.00 per share for the year ended March 31, 2022 against ¥12.00 per share paid a year ago. Dividend payment commencement date is on June 13, 2022.
공고 • Apr 07M3, Inc. to Report Q4, 2022 Results on Apr 27, 2022M3, Inc. announced that they will report Q4, 2022 results on Apr 27, 2022
Board Change • Mar 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. Director Kazuyuki Izumiya was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.